PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “seroconversion”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 685 records · Page 38Linked to original sources
PubMed2000

Study of the safety, immunogenicity and seroconversion of a hepatitis-B vaccine in malnourished children of India.

Sixty rural children who were seronegative for HBV markers received three doses of 10 microgram of a new Hepatitis-B vaccine, Revac-B (1 ml of vaccine contains 20 microgram recombinant surface antigen) that was formulated from hepatitis-B surface antigen expressed in a recombinant strain of Saccharomyces cerevisiae. Vaccines were administered on a 0, 30 and 60-day schedule. Levels of anti-HBs titres were determined on the 30th, 60th and 90th days following the initial injection. None of the participants in the trial had serious adverse reactions and the frequencies of minor side effects were minimal. No clinically important adverse effects which could be considered as directly related to the vaccination were recorded. The volunteers showed a very good immune response and were seroprotected on the 30th day after the first dose of vaccination. The present study revealed that the new vaccine, Revac-B is highly immunogenic and is well tolerated.

Child↗
PubMed2001

Establishment of latency associated with glycoprotein E (gE) seroconversion after bovine herpesvirus 1 infection in calves with high levels of passive antibodies lacking gE antibodies.

This study was conducted to investigate the glycoprotein E (gE) antibody response raised after inoculation with a low infectious dose of bovine herpesvirus 1 (BHV-1) in six calves possessing high levels of passive immunity from cows repeatedly vaccinated with gE deleted marker vaccine. Four out of the six calves developed gE antibodies 3-5 weeks after infection, whereas the two other ones remained seronegative to gE. After 5 months of infection, the six calves were treated with dexamethasone. Virus was only re-excreted by the four calves which previously seroconverted against gE. The two other calves became seronegative against BHV-1, 30-32 weeks after infection. A second dexamethasone treatment performed 11 months after infection failed to demonstrate a latent infection in these two calves. Moreover, the lack of identification of a cell-mediated immune response, after the two dexamethasone treatments, and the failure to detect BHV-1 DNA sequences in trigeminal ganglia strongly suggest that these two calves were not latently infected. In conclusion, the presence of high levels of maternal immunity lacking gE antibodies does not prevent latency after infection with a low titre of BHV-1. Moreover, latency is associated with a serological response to gE. These results confirm that the gE deletion is a good marker to identify young calves latently infected with a field virus.

Animals↗